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In the United States, the number of colon and breast cancer cases that are attributed to 
physical inactivity lead the exercise-associated cases of heart disease and type II diabetes. For 
the millions of people in the United States burdened with breast cancer, there is a noted 
substantial risk reduction with increased physical activity. Previous research has investigated 
skeletal muscle’s endocrine-like potential on inflammation and cancer metabolism; however 
there is limited investigation into exercise-facilitated suppression of cancer’s major anabolic 
pathway, the mechanistic target of rapamycin (mTOR) pathway. While previous cancer research 
has established that mTOR’s activity is dysregulated in cancer, little is known about the impact 
of exercise on the regulation of anabolic/proliferative features of breast cancer cells, nor has 
exercise been evaluated as a mediator of muscle and cancer crosstalk. This project’s objective is 
to determine how exercise is affecting the biological regulation of tumorgenesis (a critical 
component of treatment innovation) via the mTOR pathway, and how that regulation is mediated 
by skeletal muscle contraction. 
While research efforts and analyses about the mTOR pathway have led to key insights 
into its regulation of apoptotic and autophagic signaling in cancer, these efforts do not capture 
the complete profile of mTOR control on cell growth and survival, nor address preliminary data 
indicating that cellular proliferation rates are significantly reduced in breast cancer cells treated 
with excretion factors arising from contracting skeletal muscle (“exercise”).  
The work presented here-in utilizes a research approach consisting of cell culture and 
animal models to investigate key mechanistic foundations that underlie the biological regulation 




cancer cell line, a hemicorpus hind limb perfusion (HHLP) surgery, and pharmacological 
interventions allow for evaluation of skeletal muscle’s endocrine ability, global protein 
synthesis, signal transduction and gene expression. The investigators’ consideration of muscle-
cancer crosstalk via exercise lays the foundation for future evaluation of muscle-derived 
biomolecules (ie. microRNA) as a potential crosstalk mediators.  
This project’s successful completion proposes key mechanistic foundations that underlie 
the biological regulation of breast cancer, contributing greatly to science’s efforts towards novel 
translational investigation of the beneficial relationship between muscle and cancer crosstalk. 
Establishing a casual role for exercise as primary cancer prevention would have major 
translational impact in cancer prevention and patient survivorship, with even a small reduction in 
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1. INTRODUCTION  
 
The burden of breast cancer affects over 2.8 million women in the United States, with an 
estimated 268,600 new cases in 2019 alone, thus accounting for 30% of all new cancer diagnoses 
in women alone [1]. However, this burden can be reduced with exercise. Exercise has been 
shown to elicit beneficial effects in the treatment and prevention of breast cancer in addition to 
improved immune response with evidence of decreased risk with increased physical activity [2, 
3]. The role of exercise as a key player in reduction of tumor growth has been noted since the 
late 1960s [4, 5], yet most research has focused on the efficacy of physical activity in cancer 
prevention, leaving the physiological mechanisms less understood, even in rodent models [2, 6, 
7]. Centrally, proposed mechanisms behind a noted 20-40%% reduction in cancer risk [2, 8, 9] 
include alterations in whole body conditions such as body composition and improved 
metabolism, in addition to circulating adipokines, hormones and inflammatory makers [10-18].  
While these systemic modifications undoubtedly contribute to improved prognosis, they can not 
explain the association of isolated muscle contractions to decrease tumor growth noted in 
animals models. Investigations into tissue specific contributions to improved prognosis provide 
mechanistic insights and thusly propose means of tissue and cancer crosstalk. 
 
 Skeletal Muscle As An Endocrine Organ 1.1.
Underappreciated by many is skeletal muscle’s ability to release molecules during repetitive 
contractions into the systemic circulation. These molecules, termed “myokines”, are known to 
alter signaling pathways, associated with homeostasis and inflammation, both of which are 
prominent in cancer patients [8, 19-22]. F-substance (“fatigue” substance) and growth retarding 
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tumoricidal substance isolated from both in vivo and ex vivo approaches have demonstrated 
delayed mitotic rate and inhibited tumor progression in vitro and in vivo [4, 21, 23, 24]; however 
isolated cellular mechanisms pertaining to cell growth have not been identified. Using perfusate 
collected from our lab, Westerlind et al [25] demonstrated increased rates of apoptosis 
concomitant with unaltered mitotic capacity (ability of non-apoptosed cells to daughter) in 
perfusate treated MCF7 cells. The increase in apoptosis is consistent with other investigators 
who also noted decreased proliferations rates both in culture and in tumor bearing animals 
treated with perfusate either by subcutaneous injection [25] or with exercise intervention [4, 21, 
24, 26]. 
Advancement in biochemical and detection technologies have allowed the identification of 
microRNA (miRNA), a class of small, non-coding RNAs ~22 nucleotides in length. The miRNA 
system is an endogenous mechanism of gene regulation, controlling 30% of overall gene 
expression primarily through translational repression [27]. Skeletal muscle is a potent reservoir 
of these small molecules. Gene expression studies have identified hundreds of miRNA that are 
dysregulated in disease states. In cancer cells, control of oncogenes and tumor suppressors have 
been demonstrated by functional studies [28, 29] 
 
 Cellular Anabolism 1.2.
Anabolism is a key physiological process contributing to cell growth, and yet, in relation 
to cancer and alternative chemotherapeutic approaches, it remains poorly utilized. While the 
majority of basic science experimental evidence supports an inhibition of mammary 
tumorigenesis with exercise [30-36], these investigations can only provide insight into cell 
survival and programmed cell death. With the knowledge that cell cycles are highly integrated 
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(Figure1), it is significant to note that there has been neglect in evaluating changes in the 
anabolic state of a cancer cell.  
 




Changes in mitotic capacity and proliferation can both be attributed to changes in anabolism and 
global protein synthesis; thus, it is proposed that muscle-perfusate treated cells/tumors may have 
delayed growth rates (ie. global protein synthesis) which significantly contributes a delayed 
attainment of sufficient cellular mass required to mitose. As such, the comparison of both 
cellular physiological processes associated with mitosis and proliferation provide a more 
complete picture of exercise’s impact on breast cancer. Both cell growth and proliferation are 
regulated by signaling pathways sensitive to anabolic stimuli, such as nutrients, oxygen 
availability, growth factors and environmental stimulants. As such, understanding the activation 
and signal transduction within these pathways provides a logical starting point to investigate 





The mechanistic target of rapamycin (mTOR) signaling pathway (Figure 2) is central to 
multiple cell cycle and survival mechanisms. The mTOR kinase coordinates environmental 
stimuli and intrinsic feedback loops to regulate cell growth, cellular proliferation and survival, all 
of which are vital for normal cell function. However when this pathway is dysregulated or 
mTOR activity is aberrant, such as in cancer, it can lead to the hyperactivation of mTOR signals 










The mTOR protein associates with other proteins to define its complex, and ultimately its 
downstream effectors. The mTORC1 is a heterodimer protein kinase defined by its associated 
proteins Regulatory-Associated Protein of mTOR (RAPTOR) and Mammalian Lethal with 
SEC13 protein 8 (mLST8). The complex is further accessorized with inhibitory proteins 
PRAS40, and DEP domain-containing mTOR-interacting protein (DEPTOR). The mTORC2 
complex is defined by mTOR’s association with Rictor, the Rapamycin insensitive counterpart. 
 
5 
This complex also is accessorized by DEPTOR and mLST8, in addition to Protein Associated 
with Rictor (PROTOR) and stress-activated protein kinase-interacting protein-1 (mSINI).  
Signal integration by mTOR is primarily through three nodes: 1) Tublerosclerosis complex 
(TSC) integrating growth factors, stressors, and energy, 2) RAPTOR and PRAS40 integrating 
energy and growth factor, respectively, and 3) lysosomal membrane association using the RHEB 
axis for nutrient interaction [40]. While mTORC1 activity is potently anti-apoptotic, most 
investigation into its role in the biological regulation of cancer has been directed towards 
apoptotic and autophagic signals [23, 25, 45-47] with minimal efforts directed at cellular 
anabolism occurring concomitantly or separately. Active mTORC1 modulates two separate 
downstream translational regulators, ribosomal protein S6 kinase (S6K) and eukaryotic initiation 
factor 4E (eIF-4E)-binding protein (4E-EBP1) [48]. The S6K pathway is activated upon 
phosphorylation, and thusly functions in RNA processing and protein biogenesis to increase 
cellular size, which is the limiting factor for cell division [49-52]. Additionally S6K is a 
proponent of multiple feedback loops targeting upstream PI3K-Akt and Rictor-Akt signaling [53, 
54] thus contributing to cross-complex interplay. 
Although first discovered in the early 1990s, the much of what is known about 
serine/threonine mTOR has come through investigations of a canonical inhibitor, Rapamycin 
(also known as sirolimus). Discovered in the early 1970s, this macrolide fungicide was originally 
developed for use as a clinical immunosuppressant [55]. It exerts inhibition through allosteric 
binding at the FKP 12 domain of the cell-cycle-specific kinase, TOR (Target of Rapamycin) to 
generally slow proliferation and reduce cell size. Notably, response to rapamycin varies widely 
amongst cell types. Moreover, its effect on mTORC1 substrates S6K1 and 4E-BP1 vary in ability 








Figure 3. mTOR Inhibition via Pharmacology 
A schematic representation of the mTOR gene domain and proposed domain targets of Rapamycin and Torin 1 inhibition. 
Adapted from “Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.” M. Renna, 





While S6K1 activity is completely inhibited by rapamycin treatment, the more intricate co-
ordination of multiple 4E-BP1 phosphorylation sites results in only partial and transient 
inhibition, mediating some rapamycin resistant function [56, 57]. As investigations into the 
interplay between the two complexes continues to provide pro-survival feedback loops and 
sources of self-regulation (Figure 4), biochemical innovation continues into second and tertiary 
generations of rapalogs and mTOR inhibitors in hopes or success in future clinical trials. 
Emerging as a key protein in the mTOR signaling pathways, DEPTOR is endogenous 
regulator of mTOR activity. DEPTOR is an mTOR binding protein which inhibits the mTORC1 
and mTORC2 activity, and whose expression is low in most cancers [37, 40, 43, 58, 59]. 
Investigation of protein has gained momentum over the last ten years, primarily focusing efforts 
into understanding the mTOR-DEPTOR interaction and implications on cell growth and 
proliferation in vitro. These efforts have mainly addressed apoptotic and autophagy pathways 
[29, 60-69]. Unlike the mTOR kinase, which aberrant hyperactivity is consistent through out 
most cancers, the mTOR-DEPTOR relationship is less predictable. Specifically in breast cancer, 
DEPTOR expression is known to be low and is a defining characteristic of metastatic and 








the MDA-MD-231 cell line [70]. To date, research efforts has focused on induced DEPTOR-
suppression during re-sensitization to apoptotic stimuli [40] , upregulated DEPTOR in aggressive 
cancer cells [59, 70], DEPTOR degradation process evaluation [58, 59] and understanding the 
feedback loops in signals arising from DEPTOR-mTOR interaction [37, 38, 41, 42, 44, 71]. 
However, mTOR-DEPTOR interaction in epithelial MCF7 cells in direct response to exercise or 
contraction medium is not fully understood, nor its relation to cellular anabolism and protein 
synthesis of a breast cancer cell. 
 
Protein Synthesis 
Anabolism is the coordinated metabolic activity that allows cells to produce 
macromolecules [72]. Protein synthesis rate is an indicator of metabolic activity and thusly 
contributes to a cell’s anabolic profile. The mTORC1 downstream network highly regulates 
protein synthesis by co-coordinating aspects of cap-dependent translation, translation elongation, 
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mRNA biogenesis and ribosome biogenesis (Figure 5). Cumulative protein synthesis is resultant 
from both de novo (i.e. nutrients) and recycled amino acid incorporation [73], of which cell 
growth is highly dependent upon [57, 72, 74, 75]. To allow for the dynamics of protein synthesis, 
an appropriate method to assess global fractional synthesis rate (FSR) in a cancer cell exposed to 
simulated exercise is the deuterium oxide (2H2O) methodology. This method allows for the 
incorporation of a stable isotope over physiologically relevant conditions, such as 24h (daily FSR 
value), thus assessing long-term biosynthesis of macromolecules and accounting for fluctuations 
in cellular activity [73, 76-80]. Furthermore, with the objective to maintain the translational 
application of study findings, use of 2H2O as stable isotope tracer accounts for the dynamic 
changes in both skeletal muscle behavior and tumor microenvironment with exercise (i.e. 
nutrient availability, hormone circulation, mechanical stimuli) in patients existing under free-
living conditions. To our knowledge, cumulative fractional protein synthesis (24h FSR [80]) of a 
cancer cell following exercise or pharmacological intervention has not been directly assessed. As 
such, elucidating the integration of signaling events that contribute to protein synthetic response 
with both illustrate and contribute to a complete anabolic profile of breast cancer cells exposed to 









 Endogenous Regulation of Gene Expression 1.3.
Proteins dictate cell function, but what proteins are found in our cells are dictated by the 
messaging transcripts that code for their production. The amounts and types of those coding 
transcripts, known to scientists as messenger RNA (mRNA), dictate protein levels and ultimately 
reflect cellular function. When the transcription rate of certain mRNA molecules fluctuates 
and/or the translation of those mRNA into target proteins becomes irregular, cellular homeostasis 
can become dysregulated. This process, known as Gene Expression, is an area of high 
importance when investigating causes of human diseases, such as breast cancer. Researchers are 
diligently investigating how exercise may alter tumor gene expression, limiting how and if the 
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cancer cells proliferate and tumors grow.  Using pharmacological and animal models of exercise, 
scientists can manipulate the transcription-translation process within breast cancer cells, 
evaluating changes in protein-signaling pathways vital to growth and normal cell function. Like 
the mTOR pathway that can influence selective translation of transcripts, gene expression takes 
coordination from a lot of moving parts from delicate cellular machinery to ideal environmental 
conditions, making many possible check points between transcription and translation available 
for therapeutic intervention.  
 
 Purpose 1.4.
The purpose of the work described in the following dissertation 
was to establish a potential mechanistic basis for muscle and 
breast-cancer crosstalk with exercise. 
 
Our long-range goal is to explore the therapeutic mechanisms of exercise associated with 
protein turnover/cell growth in normal vs cancerous cells. Our objective for this proposal is to 
characterize exercise’s impact on breast cancer anabolism and investigate the mTOR-pathway in 
epithelial breast cancer in vitro. Our rationale underlying this research was that once the 
mechanistic basis for muscle and cancer crosstalk is known, targeted pharma-, chemo-and 
exercise therapeutic strategies may be used to protect at-risk populations. 
Each of the following studies are in manuscript format, complete with a brief 
introduction, methods specific to the study, results and discussion. A general conclusion of the 
combined studies can be found in the last chapter. The underlying theme of the work here-in is 
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that contracting skeletal muscle exerts its influence on the regulation of mTOR signaling in 
cancer cells.  
The first study in this dissertation was divided into two portions. The first portion of the 
study established that the hemicorpus hind limb preparation protocol used during studies 1 and 3 
was sufficient to suppress rates of protein synthesis in breast cancer cells exposed to muscle 
released factors for 24h. This assessment was made using an established deuterium (2H2O) 
isotope tracer method [81, 82], modified for in culture. The second portion of the study 
attempted to elucidate whether skeletal muscle contraction imparted regulation on the mTOR 
signaling pathway in MCF7 breast cancer cells. If so, then one may suspect that this finding 
could have important implications for exercise prescriptions currently advocated by physicians 
and provide insight into biological mechanisms responsible for noted decreases in tumor growth 
and improved prognosis in physically active patients. Our colleagues addressed the potential for 
altered mTOR activity via apoptosis in response to exercise with contraction perfusate collected 
in our lab [25]. Westerlind et al. demonstrated not only increased apoptosis in cells treated in 
vitro with perfusate of stimulated muscles [25], but increased tumor time to latency and tumor 
growth retardation with moderate exercise training in vivo [23]. The protein regulating cellular 
apoptosis is the same protein that regulates cell growth and proliferation, and methods used by 
Westerlind et al. do not address changes in the anabolic activity, nor capacity, of the cancer cells. 
Currently, no studies exist regarding the impact of exercise on the anabolic response on breast 
cancer and whether specific proliferative pathways are altered leading to suppressed cell growth 
and/or induction of apoptosis. 
The second study in this dissertation was divided into two portions. The first portion 
established that pharmacological administration of mTOR inhibitors suppress protein synthesis 
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and consequent anabolic signaling, with a rescue of DEPTOR protein content. This assessment 
was made using MCF7 breast cancer cells treated with known mTOR kinase inhibitors 
Rapamycin and Torin1 [83]. Assessment of rates of cellular protein synthesis was made using 
the same modified deuterium (2H2O) isotope tracer method used in study 1. The second portion 
of the study attempted to disclose whether discrepancies in protein expression between study 1 
muscle-perfusate treated cells and study 2 mTOR inhibitor treated cells was due to 
bioavailability of messenger RNA transcript encoding mTOR growth and proliferative factors. 
By using gene expression inhibitors ActinomycinD (transcription inhibitor) [84] and 
Cycloheximide (translation inhibitor) [85], this investigator could observe whether mRNA 
transcription and/ translation was dependent on mTOR activity. No studies exist regarding the 
dependency of mTOR proliferative factors’ transcription- translation on mTOR kinase activity in 
breast cancer cells.  
The third and last study in this dissertation was divided into two portions.  The first portion 
established that the bilateral hemicorpus hind limb perfusion was a sufficient model of skeletal 
muscle contraction, which isolated contracting skeletal muscle as direct contributor to cancer 
crosstalk. The second portion examined miRNome profile of perfusate released from contracting 
skeletal muscle and the ability of myomiRs to enter systemic circulation. The ability of skeletal 
muscle to secret factors into systemic circulation to exert para- and autocrine functions within the 
body are well documented [8, 19-22]. Recent studies have shown that skeletal muscle is potent 
reservoir of miRNA (myomiR), and possesses the ability to release myomiR into circulation 
passively and actively. The mechanisms associated with myomiR delivery to breast cancer cells 
is not completely understood, but may contribute to altered gene expression and anabolic activity 
of breast cancer cells exposed to muscle-contraction medium.  
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Given breast cancer’s prevalence in the United States, and the recognized benefit of exercise 
in breast cancer patients, there is a critical need to translate how exercise impacts breast cancer 
proliferation in order to vertically move the field’s understanding of muscle and breast cancer 
crosstalk, and of the biological regulation on breast cancer. 
 
 Specific Aims 1.5.
Study 1 
1. To determine if breast cancer anabolism is altered by simulated exercise.  
Study 2 
2. To identify whether the altered proliferation of breast cancer cells is 
mediated by cellular signal transduction of specific proliferative pathways.  
3. To determine if cellular proliferation of breast cancer cells is mediated by 
changes of cellular expression of proliferative factors.  
Study 3 
4. To profile the ability of muscular contraction to facilitate the release of 
endogenous microRNA into systemic circulation 
 
This project’s successful completion provides key mechanistic foundations that underlie the 
biological regulation of breast cancer, vertically moving the field towards novel translational 





Given our preliminary data demonstrating decreased proliferation of MCF7s following 
exercise exposure, our central hypothesis is that the impact of exercise on breast cancer is by 
directly influencing mTOR and its associated pathway.  
 
The following hypotheses are stated in the Null format. 
 
Study 1 
1. Ho: Anabolic activity of breast cancer cells will not be affected by exposure to 
exercise perfusate medium. 
Study 2 
2. Ho: Pharmacologically altered mTOR activity will not result in altered 
anabolic activity and expression of inhibitory proteins compared to control 
cells. 
3. Ho: mTOR activity does not affect the expression of inhibitory proteins 
and activation of downstream anabolic signals in breast cancer cells.  
Study 3 
4. Ho: Endogenous skeletal muscle microRNA secretion will not be different 







 Significance and Innovation 1.7.
Significance 
In the United States, breast cancer is the most common cancer in women [86] with more than 
2.8 million women with a history of breast cancer and an estimated 238,130 new cases 268, 600 
new cases in 2019 alone [1]. Exercise has been shown to elicit beneficial effects in the treatment 
and prevention of cancer,  in addition to decreased cancer risk with increased physical activity 
[2, 3]. The role of exercise as a key player in reduction of tumor growth has been noted since the 
late 1960s [4, 5], yet most research has focused on the efficacy of physical activity in cancer 
prevention, leaving the biological mechanisms of exercise-associated 20-40%% reduction in 
breast cancer risk less understood [2, 8, 9], even in rodent models [2, 6, 7].  
Skeletal muscle has established a positive association with regard to enhanced activities of 
daily living and improved quality of life, and its protective effect on multiple metabolic disease 
states [37, 57, 87]. Underappreciated however, is that skeletal muscle exhibits an endocrine-like 
behavior during exercise where exercise-induced ‘hormones’ are released into circulation in both 
rodents and humans post muscular contraction [19, 20, 35, 88]. Specifically, contracting muscle 
releases “myokines” (hormones), which are molecules that effect signaling pathways involved 
with muscle homeostasis, inflammation, and colon cancer, amongst others [19, 22, 89, 90]. The 
earliest established connection between myokines, previously “fatigue substance”, and inhibited 
tumor progression dates back to the early 1960s. Extract released from rat muscle during passive 
electrical-stimulated contraction resulted in significant tumor growth inhibition when 
administered via subcutaneous injections into tumor-bearing rodents [4, 21, 24]. Recently, our 
lab has contributed to the field’s current findings that in situ produced myokines significantly 
inhibits breast cancer proliferation and increase rates of apoptosis when cells are treated with the 
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contraction medium in vitro [22, 26, 91, 92]. As such, we hypothesize that impact of exercise on 
breast cancer is by directly influencing mTOR activity, which subsequently alters downstream 
anabolic signaling, anabolic activity and attenuates cell proliferation rates, forcing cells into 
senescence/apoptosis. The cellular mechanism between exercise and suppressed proliferation, 
growth and anabolic magnitude appears to be facilitated via the inhibition of the mTOR pathway. 
The field has demonstrated direct crosstalk between muscle and breast cancer via an mTOR 
regulated cellular state, apoptosis [23, 25]; however the mTOR’s anabolic activity, regulation of 
cellular proliferation, and survival feedback loops remain unacknowledged in the physiological 
paradigm. While our proposed investigation into the mTOR regulation in cancer is not entirely 
novel, the context of exercise as a physiological mechanism to exert control over mTOR’s 
anabolic activity as a means of therapeutic control on cell survival is. 
Currently there is an evolving appreciation for exercise-combined therapies advocated by 
clinicians [93-96]. Given breast cancer’s prevalence in the United States, and the recognized 
benefit of exercise in breast cancer patients [93-96], identifying and understanding mechanistic 
impact of exercise on cancer will advance research and may lead to new treatments. Establishing 
a casual role for exercise as primary cancer prevention would have major translational impact in 
cancer prevention and patient survivorship, with even a small 1% reduction in incidence of 
cancer resulting in $500 billion in health care savings. We believe that our investigation of 
mTOR and determination of its role in breast cancer cell signaling will vertically advance the 
field’s conceptualization of muscle, exercise and explain noted improved prognosis in exercising 






Huge challenges exist to identify and investigate biological regulation of exercise to noted 
medical benefits.  One of the factors hampering the translation of knowledge from preclinical 
studies to the clinic has been the limitations of in vitro diseases models [97]. In this project, we 
are moving beyond the status quo of mTOR regulation of cell survival in cancer [37, 42, 44, 47, 
98] by exposing the potential chemotherapeutic significance of exercise-altered mTOR signaling. 
We are hypothesizing that altered mTOR activity via exercise and pharmacologically will be 
concomitant with diminished anabolic activity within epithelial breast cancer cells, attenuating 
proliferation rates, and forcing cells into senescence/apoptosis. The scientific premise of this 
study rests on the lack of integration between skeletal muscle’s purported endocrine 
function that considers the impact of exercise-induced molecules on metabolic diseases and 
the strong literature indicating that perfusate collected from contracting skeletal muscle 
has a chemotherapeutic effect on breast cancer growth and proliferation. To our knowledge, 
the existing body of literature has not addressed impact of molecules arising from muscle during 
contraction on other cell types, like cancer, nor considered exercise as a mediator of muslce-
cancer crosstalk. Thus, the contribution of the prosed project is expected to be a delineation of 
the potential mechanisms by which exercise improves cancer prognoses and the cellular control 
by directly influencing a possible culprit for uncontrolled proliferation in cancerous cells. This 
contribution will be significant because it will directly determine how exercise is affecting the 
biological regulation of tumorgenesis (a critical component of treatment innovation), and how 





2. MTOR GENE EXPRESSION IS A TARGET OF MUSCLE-BREAST 
CANCER CROSSTALK WITH EXERCISE 
 
 Summary 2.1.
Proteins dictate cell function, but what proteins are found in cells are dictated by the 
transcription and translation of the coding message transcripts. The mechanistic target of 
rapamycin (mTOR) is a heterotrimeric protein kinase and its signaling pathway is vital for 
normal cell function, which has the ability influence selective protein translation. Comprised 
mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2), both the downstream and 
upstream effectors of this protein regulate growth and cellular proliferation. When this pathway 
is dysregulated, such as in cancer, it can lead to hyperactivation of signals which promote cell 
proliferation and protect against cell death.  In this study, the anabolic profile of epithelial breast 
cancer cells was evaluated to identify changes in growth and proliferation mediated by muscular 
contraction and pharmacology. Hemicorpus Hind Limb-Perfusion (HHLP) preparation with 
electrical stimulation of rats served as a model of resistance exercise. Through a combination of 
cell counts, immunoblotting, and gas chromatography-mass spectrometry, mTOR was identified 
as a key mechanistic protein whose anabolic activity may be influenced by exercise facilitated 
muscle and breast cancer crosstalk. When MCF-7 cancer cells were treated with perfusate 
collected during muscle contraction, a significant inhibition of proliferation was noted alongside 
diminished mTOR activity and decreased protein synthesis rates. Given breast cancer’s 
prevalence in the United States, and the recognized benefit of exercise in breast cancer patients, 
identifying and understanding the mechanistic impact of exercise on cancer will advance 




In the United States, breast cancer is the most common cancer in women [86] with more 
than 2.8 million women with a history of breast cancer and an estimated 268,600 new cases in 
2019 alone [1, 99].  
Exercise has been shown to elicit beneficial effects in the treatment and prevention of 
cancer in addition to improved immune response with evidence of decreased risk with increased 
physical activity [2, 3]. The role of exercise as a key player in reduction of tumor growth has 
been noted since the late 1960s [4, 5], yet most research has focused on the efficacy of physical 
activity in cancer prevention, leaving the biological mechanisms of exercise-associated 20-
40%% reduction in breast cancer risk less understood [2, 8, 9],even in rodent models [2, 6, 7].  
 
Mechanistic Target of Rapamycin (mTOR) 
The mechanistic target of rapamycin (mTOR) signaling pathway is centric to multiple 
cell cycle and survival mechanisms. The mTOR kinase coordinates environmental stimuli and 
intrinsic feedback loops to regulate cell growth, cellular proliferation and survival, all of which 
are vital for normal cell function. The mTOR protein associates with other proteins to define its 
complexes (mTORC1 and mTORC2), and ultimately influencing metabolic and cellular changes. 
The mTORC1 is a heterodimer protein kinase defined by its associated proteins regulatory-
associated protein of mTOR (RAPTOR) and mammalian lethal with SEC13 protein 8 (mLST8). 
The complex is further accessorized with inhibitory proteins PRAS40, and DEP domain-
containing mTOR-interacting protein (DEPTOR), The mTORC2 complex is defined by mTOR’s 
association with Rictor, the Rapamycin insensitive counterpart. This complex also is 
accessorized by DEPTOR and mLST8, in addition to  protein associated with Rictor (PROTOR) 
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and stress-activated protein kinase-interacting protein-1(mSINI). When the mTOR kinase is 
active, it positively regulates many anabolic processes of the cell, and its stimulation can lead to 
both positive and negative intrinsic feedback mechanisms which can result in altered activation 
[100]. For example, when the mTOR pathway is dysregulated, such as in cancer, it can lead to 
the hyperactivation of signals that serve to both promote cellular proliferation and protect against 
apoptosis [37-44]. mTORC1 activity is potently anti-apoptotic and anti-autophagic; its activation 
stimulates amino acid uptake and protein synthesis [101]while suppressing autophagy [102]. Its 
downstream targets (Figure 6), most notably ribosomal protein S6 kinase (S6K1/p70s6k) and the 
translational repressor eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), are indicators 
of mTORC1 activity and sources of negative feedback signals [45, 48, 53, 103-110]. DEPTOR is 
an mTOR binding protein which inhibits the mTORC1 and mTORC2 activity, and whose 
expression is low in most cancers [37, 40, 43, 58, 59]. 
To date, research efforts have focused on induced DEPTOR-suppression during re-
sensitization to apoptotic stimuli [40] , upregulated DEPTOR in aggressive cancer cells [59, 70], 
DEPTOR degradation process evaluation [58, 59] and understanding the feedback loops in 
signaling arising from DEPTOR-mTOR interaction [37, 38, 41, 42, 44, 71]. However, mTOR-









Anabolism is the coordinated metabolic activity that allows cells to produce 
macromolecules [72]. mTOR is a master growth regulator that promotes anabolism [107]. 
Moreover, the mTOR kinase is a master switch for a cells induction from quiescence into 
growth, whose activity facilitates the direction of post-transcriptional programming of growth-
specific genes [111]. While both mTORC1 and mTORC2 function in growth control, signals 
controlling protein synthesis machinery and the production of proteins are primarily transmitted 
through complex 1. mTORC1 is tightly linked to several steps of protein synthesis including 
ribosome biogenesis, translation initiation and elongation [100]. Specific mTORC1 active-site 
inhibitors have been shown to significantly reduce overall rates of protein synthesis in 
proliferating cells [56, 107, 112]. To date, no studies exist that have systematically assessed rates 
of global protein synthesis in breast cancer cells, nor how that anabolic function is affected by 




Pharmalogical Control of mTOR Activity 
The anabolic process of protein synthesis is energetically expensive, thus if the cell is in a 
state of survival, the anabolic process may be suppressed allowing the cell to senesce and protect 
itself to current apoptotic injury. Recent studies support that the two distinct mTOR complexes, 
although different in their biochemical and functional design, share common upstream signals 
[100]. Early work unveiled that mTOR catalytic activity can be altered via pharmacology. 
Rapamycin, an allosteric inhibitor, mostly affects mTORC1 activity and the phosphorylation and 
activation of its downstream target S6K1 and 4E-BP1, thus primarily inhibiting cell growth, cell 
proliferation and cell cycle progression [45, 113, 114]. While rapamycin and its analogues are 
well tolerated by patients, only a minority of patient, including breast cancer patients, show 
positive response to treatment. Its inefficiency at suppressing translation in mammalian cells via 
4E-BP1 [45, 57, 83, 115] has led to second generation inhibitors which are ATP competitive, 
such as Torin1 [56, 83, 115, 116]. Torin1 has the ability to inhibit mTORC2 activity. This is 
significant in the context of cancer, for without suppression of mTORC2 activity, the complex’s 
“pro survival function” via feedback signaling is maintained, and mTORC1 can remain 
transiently active, leading to continued proliferation [57, 83]. As such, the established overlap of 
cell cycle regulation and integration of feedback signals associated with anabolic activity provide 
urgency for investigation of mTOR as a centric mechanism for the biological regulation of breast 
cancer. 
 
Pharmalogical Control of Gene Expression 
Proteins dictate cell function, but what proteins are found in our cells are dictated by the 
messaging transcripts that code for their production. Like the mTOR pathway that can influence 
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selective translation of transcripts, gene expression takes coordination from a lot of moving parts 
from delicate cellular machinery to ideal environmental conditions, making many possible check 
points between transcription and translation available for therapeutic intervention. 
ActinomycinD and Cycloheximide are antibiotics which have previously been used to 
inhibit precursor incorporation into macromolecules, thusly allowing the investigators to study 
the role of RNA and protein synthesis [117-119]. ActinomycinD is a transcriptional inhibitor 
which blocks the progression of RNA polymerases in eukaryotic cells. Cycloheximide is a potent 
protein synthesis inhibitor which, in MCF7s, has been found to minimize cell death whilst 
suppressing global protein synthesis [120, 121]. In combination, these compounds are key tools 
in evaluating whether there are changes in specific transduction intermediates associated with 
changes in anabolic proteins. Furthermore, they are conducive to identifying whether changes in 
anabolism are due to de novo protein synthesis of the other cellular processes such as 
ubiquination and protein degradation. Overall, understanding the transcriptional-translational 
regulation of altered proliferative factors within the mTOR cascade will highlight the potential 
for endogenous sources of proliferation regulation in cancer cells, such as microRNA. 
 
The purpose of these directed studies is to develop an experimental approach to 
determine if cellular proliferation of breast cancer cells is mediated by changes of cellular 
expression of proliferative factors, using an in vitro pharmacology model. We are hypothesizing 
that altered mTOR activity via pharmacologically will be concomitant with lowered gene 






Hemicorpus Hind Limb Perfusion 
Female Wistar rats (N=10) 8-12 weeks of age were purchased from Charles River 
Laboratories (Wilmington, MA). All procedures were approved by the Institutional Anima Care 
and Use Committee at Texas A&M University. Animals were housed two-rats per cage under 
standard 12h photoperiod, provided with normal Rat Chow with water ad libitum. Following a 
two day acclimation period after arrival, animals underwent a non-survival Hemi Corpus Hind 
limb Perfusion preparation (HHLP) (Figure 7) as described previously [91, 92, 122-125]. Briefly, 
midline to caudal end of the animal was surgically prepared so both hind limb limbs could be 
perfused with an oxygenated Krebs-Heinseliet Buffer during electrically stimulated muscle 
contraction. Electrical stimulation was administered using a stimulator (Grass Instruments, West 
Warwick, RI) and a force transducer (Warner Instruments, Harvard Bioscience Inc., Holliston, 
MA) at a surgically exposed sciatic nerve on a single hind limb of the animal. Perfusate medium 
was maintained at 31.7°C using a bipolar temperature controller (Model #CL-100, Warner 
Instruments, Harvard Bioscience Inc., Holliston, MA) and administered at a flow rate of 
12ml/min, by peristaltic pump (MPL 8-Channel) (Watson Marlow, Marlo, United Kingdom).  
Perfusion sample collection is depicted in Figure 8. During perfusion, medium was 
collected on ice in 50ml sterile conical tubes (Corning Inc., Corning, NY) before electrical 
stimulation (Non-Stim, NS), during electrical stimulation (E-Stim, ES), and following electrical 
stimulation (Post-Stim, PS). Following collection, samples was centrifuged at 2500 rpm at 4°C 


















Human MCF7 cells were obtained from American Type Culture Collection (ATCC, 
Manassas, VA). Cells were cultured in 20mmcm dishes (Corning Inc., Corning, NY) with 10ml 
growth media (GM) containing Dulbecco’s Modification of Eagle Medium (DMEM) (Corning, 
Mediatech INC., Manassas, VA), supplemented with 5%(v/v) Fraction V Fetal Bovine Serum 
(FBS) (VWR International, Randor, PA) and 1% (v/v) Penicillin/Streptomycin (BioVision, 
Milpitas, CA). Cells were maintained GM at 37°C in a humidified atmosphere containing 5% 
CO2 until 60% confluent. 
Cell Harvest Protocol. Growth medium from plates allocated for western blot or RT-
qPCR analysis was aspirated and 3 ml of cold Phosphate Buffer Solution (PBS) (VWR 
International, Randor, PA) was applied to each plate. Growth medium from plates allocated for 
protein synthesis analysis was collected into 2ml microcentrifuge tubes (VWR International, 
Randor, PA) and snap frozen into liquid nitrogen and then transferred to storage at -80°C until 
analysis. All cells were collected using cell scrapers (VWR International, Randor, PA) and 
transferred to 2ml microcentrifuge tubes, and centrifuged at 130xg for 8 minutes to separate cell 
pellet from the PBS supernate solution. Supernate was discarded from each vial and cell pellet 
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samples were then snap frozen into liquid nitrogen and then transferred to storage at -80°C until 
analysis.  
For muscle perfusate (Figure 9), 10ml GM was supplemented with 10% exercise 
perfusate media collected during hind limb perfusion surgeries during non-electrical stimulation 










Cells incubated in respective media for 24h (Figure 10). All cells allocated for protein synthesis 
analysis were additionally treated with heavy water (2H2O) to yield a 4% final volume of 10ml 








For mTOR pharmacological inhibitor experiments (Figure 11), 10ml GM received 
addition of either Rapamycin (RAP) (CAT #2353, BioVision, Milpitas, CA), Torin1 (TOR1) 
(CAT #2353, BioVision, Milpitas, CA), or both (RAP+TOR1) to yield concentrations of 100nM, 









All treatment groups received equal dosing of dimethyl sulfoxide (DMSO) to serve as a vehicle 
control (VC) and incubated in respective media for 24h (Figure 12). All cells allocated for 
protein synthesis analysis were additionally treated with heavy water (2H2O) to yield a 4% final 









For gene expression pharmacological experiments (Figure 13), cells were randomly 
assigned to treatment group first by mTOR inhibitor treatments of Rapamycin (Rap, 100nM) or 
Torin1 (Tor1, 250nM), and then to transcription-translation inhibitor treatments of 
ActinomycinD-D (1ug/ml) (AdipoGen Life Sciences, San Diego, CA), Cycloheximide (25ug/ml) 








Cell control and a vehicle control (DMSO) plates were cultured alongside experimental groups 










To assess expression and activation of individual proteins within the mTOR signaling 
cascade, the following primary antibodies were used at a 1:1000 antibody/buffer ratio: DEPTOR 
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(Cell Signaling #11816), phospho-P70S6K1Th389 (Cell Signaling #2114), p70S6K1 (Cell 
Signaling #2114), phospho-AKTSer473 (Cell Signaling #2114), phospho-AKTTh308 (Cell Signaling 
#2114),  AKT (Cell Signaling #2114),  phospho-RictorThr1135 (Cell Signaling #3806), Rictor (Cell 
Signaling #2114), and appropriate HRP-linked secondary antibodies at 1:2000 antibody/buffer 
ratio. Cell pellets were homogenized and applied to gels in conjunction with molecular weight 
ladder (Lonza #193837) to verify size, separated and transferred onto blotting membranes as 
previously described.  Membranes were imaged using a FlouroCHem SP imaging system (Alpha 
Innotech, San Leandro, CA, USA) and optical density of protein bands was determined using the 
Alphaease FC software (Alpha Innotech). All bands were normalized to Ponceau S stains and 
expressed as arbitrary units. 
 
Deuterium Method 
The validity of a deuterium approach has been demonstrated by its ability to accurately 
measure muscle protein synthesis (MPS) in free-living subjects over longer periods of time in 
order to better replicate physiological relevant conditions. The method used to assess fractional 
synthesis rates (FSR) in MCF7 cells was modified from the gas chromatography-mass 
spectroscopy (Agilent 7890 GC/5975 VL MSD, Agilent Technologies, Santa Clara, CA) method 
previously described [126].  
2H20  enrichment of water soluble proteins/cell media. Briefly, cell media collected at 
harvest following 24-h of isotopic exchange between 2H20  enrichment of cell media samples and 
acetone, and frozen at -80C were thawed on ice for 15minutes. Alongside calibration standards 
(0 –5% 2 H2 O, prepared by mixing naturally labeled water with 99.9% 2 H2 O), 20ul were 
aliquotted into 2ml microcentrifuge tubes and incubated for 24-h at room temperature with 2ul of 
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10N NaOH and 4ul of a 5% (vol/vol) solution of acetone:acetonitrile. Procedural steps from this 
point on were consistent as previously described [126]. All plasma samples were measured twice 
with separate preparations, and an average value of the two runs were used for calculations. 
[2H] alanine  enrichment in MCF7 cells. Briefly, frozen cell samples (1 microcentrifuge 
tube = 1x 10cm plate, 70-80% confluence) were thawed on ice for 15mins before 
homogenization in 300ul of iced 10% TCA (Cl3CCOOH). Samples were vortexed for ~10s 
before centrifugation at 3,000 rpm for 10mins to remove unbound amino acids. Following, 
supernate was decanted, and the remaining cell pellet placed on ice. TCA treatment, 
centrifugation and decanting were repeated for a total of 3 spins before proceeding in accordance 
with previously described details procedures [126]. Fractional synthesis rates (FSR) of mixed 
proteins were calculated using the equation: 
EA X [ECM X 3.7 X t (h)]-1 X 100 
where EA represents amount of protein-bound [2H]alanine (mole% excess), ECM is the quantity of 
2H2O in cell media (mole% excess), and 3.7 represents the exchange of 2H between cell media 
and alanine (e.g., 3.7 of 4 carbon-bound hydrogen of alanine exchange with water [127]). The 
novel use of primed-constant exposure method, with the use of a deuterium oxide (2H2O) as a 
tracer, allows for assessment cumulative protein synthesis of a mixed proteins in cancer cells 
exposed various treatments. This assessment contributes to generating a complete anabolic 
profile of MCF7 breast cancer cells. 
 
Gene Expression 
RNA Isolation. Total RNA was manually extracted. Briefly, samples were manually 
extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA) and 1-Bromo-3-chloropropane 
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(Biomedical Research Centre) protocol and precipitated in isopropanol. Following, RNA was 
treated with a series of ethanol washes to prevent downstream salt inhibition, and then re-
suspended in 50ul of nuclease free water. RNA concentration was the quantified by a 
NanoDrop™ 1000 spectrophotometer (Thermo Scientific, Waltham, MA) and a Qubit 2.0 
Fluorometer (Invitrogen, Carlsbad, CA) according to manufacturers protocol. RNA integrity 
(RIN) was assessed on a 4200 TapeStation System (Agilent Technologies, Santa Clara, CA), 
which assigned a RINe value on a scale of 1 to 10. Purity and quality are summarized in Table 4 
(Appendix A). RNA samples with RINe quality values >7.5 were included in RT-qPCR assays. 
Reverse Transcription (cDNA Synthesis). Reverse transcription for cDNA synthesis was 
performed using Superscript VILO cDNA Synthesis Kit (Applied Biosystems, Carlsbad, CA) 
with 200 ng total RNA in reactions of 20ul according to manufacturers instructions. mRNA 
expression of target genes were quantified with real time PCR using Applied Biosystems 
7900HT Fast Real-Time PCR System (Carlsbad, CA). TaqMan Gene Expression assays 
(Applied Biosystems, Carlsbad, CA) for mTOR (Hs00234508_m1), DEPTOR 
(Hs00961900_m1), BTRC1 (Hs00182707_m1), FBXW11 (Hs00362667_m1), RPS6KB1 
(Hs00177357_m1), RPS6KB2 (Hs00177689_m1), 4EBP1 (Ha0060705_m1) were handled 
according to the manufacturer’s instructions. Assay details are referenced in Appendix A-Table 
5. Quantitative PCR was performed in triplicates of 20ul reactions using 1X TaqMan Universal 
Master Mix II, no UNG (Applied Biosystems, Carlsbad, CA) with pooled sample reactions 
without reverse transcriptase (-RT), as well as no template controls (NTC). Thermal conditions 
were as follows: 10min at 95°C, and 15s at 95°C with 1min at 60°C for 40 cycles. Six genes 
have been identified as potential reference genes for expression normalization using a review of 
available literature for cell type, treatment type, co-treatment and RT-qPCR design (Appendix A- 
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Table 6). Expression of target genes will be normalized to the most stable endogenous control 
using methods described by Dawes et al [64]. All data analysis will be conducted with Sequence 
Detection Software v 2.2.2 (Applied Biosystems, Carlsbad, CA). 
 
Statistical Analysis 
Muscle Perfusate Experiments. The effects of electrical stimulation and perfusate on 
expression and synthesis of proteins was assessed by one-way ANOVA followed by Fisher LSD 
post hoc test (SigmaStat 3.5; Systat Software Inc., San Jose, CA,USA).   
mTOR Pharmacology Inhibitor Experiments. The effects of pharmacological inhibition 
on expression and synthesis of proteins was assessed by one-way ANOVA followed by Fisher 
LSD post hoc test (SigmaStat 3.5; Systat Software Inc., San Jose, CA,USA).  
 
 Results  2.4.
Muscle Perfusate Experiments 
 Results of immunoblotting analysis are illustrated in (Figure 15). Expression of 
phosphorylated-p70S6K1Thr389 and ratio of phosphor-to-total p70S6K1 protein was significantly 
decreased in all treatment groups compared to CC, while ES was significantly different from NS 
and PS treated cells (P<0.05). There was no difference in total p70S6K1 protein across all 
treatment groups. Expression of phosphorylated-4EBP1Thr37/46 and ratio of phosphor-to-total 
4EBP1 protein was significantly decreased in ES and PS groups compared to CC, while ES was 
significantly different all other treatment groups (P<0.05). There was no difference in total 
4EBP1 protein across all groups. A significant increase in total DEPTOR protein expression was 
observed in ES treated cells compared to all other treated groups (p<0.05). Protein synthesis 
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analyses (Figure 16) showed a significant decrease in absolute daily FSR in both E-stim and 
Post-Stim treatment groups, compared to CC and Non-Stim groups (p<0.05) (19.3, 18.2- vs 28.1, 
31.8 %/d respectively). A significant decrease in relative % daily FSR in both E-Stim and Post-
Stim treatment groups relative to CC (p<0.05).  
 
mTOR Pharmacology Inhibitor Experiments. 
Cell counts (Figure 17) showed a significant decrease in absolute proliferation in TOR1 
and RAP+TOR1 treated cells. Immunoblot analysis (Figure 18) showed decrease in 
phosphorylated-mTORSer2448 and phospho-to-total mTOR in both RAP and TOR1 compared to 
VC treated cells. Expression of phosphorylated-p70Th389 and phospho-to-total p70S6K1 was 
decreased in both RAP and TOR1 compared to VC treated cells. There was a significant increase 
in DEPTOR protein expression in both RAP (p=0.005) and TOR1 (p=0.001) treated cells 
compared to VC. Additionally, phosphorylated-AKTSer473 and phospho-to-total AKT was higher 
in RAP treated cells compared to VC and TOR1, respectively.  Phosphorylated- RictorThr1135 and 
phospho-to-total Rictor was decreased in both RAP and TOR1 compared to VC. Protein 
synthesis analyses (Figure 19) showed decreased in absolute daily FSR in both RAP and TOR1 






Figure 15. Muscle Perfusate Experiment, Immunoblotting Results 
Protein expression data are shown in Integrated Density Units (IDV) with standard error of the mean. A) DEPTOR 
protein, B) 4EBP1 protein phosphorylated, total, phospho-to-total ratio, C) p70S6K1 protein phosphorylated, total, 






Figure 16. Exercise Perfusate Experiment, 24H Protein Synthesis Results 
Data are presented at percent of daily fraction synthesis rate (FSR) with standard error of the mean. Statistical 






Figure 17. mTOR Pharmacology Inhibitor , Cell Counts 
Data shown are absolute cell counts with standard error of the mean. Statistical significance: a= different from 






Figure 18. mTOR Pharmacology Inhibitor, Immunoblotting Results 
Error bars shown represent standard error of the mean values. Statistical significance: a= different from VC, b= 





Figure 18. Continued 






Figure 19. mTOR Pharmacology Inhibitor, 24H Protein Synthesis Results 




Gene Expression Pharmacology Inhibitor Experiments. Relative expression ratios are 
illustrated in Figure 20. A combined reference of ACTB, RPLP0 and EIF4EBP1 genes was 
found to be the most stable control for analysis (Table 1). Treatment with ActinomycinD resulted 
in inhibition of transcription, thus mRNA detected is assumed resultant of transcription activity 






Gene(s) Combinations  + S Number of Genes 
ACTB, RPLP0, EIF4EBP1 0.24 3 
ACTB, GAPDH, RPLP0, EIF4EBP1 0.25 4 
ACTB, GAPDH, EIF4EBP1 0.29 3 
ACTB, EIF4EBP1 0.30 2 
ACTB, GAPDH, RPLP0 0.31 3 
GAPDH, RPLP0, EIF4EBP1 0.33 3 
GAPDH, RPLP0 0.34 2 
RPLP0, EIF4EBP1 0.35 2 
GAPDH, EIF4EBP1 0.40 2 
ACTB, RPLP0 0.40 2 
GAPDH 0.42 1 
ACTB, GAPDH 0.43 2 
RPLP0 0.44 1 
EIF4EBP1 0.47 1 
ACTB, PUM1, GAPDH, RPLP0, EIF4EBP1 0.56 5 
PUM1, GAPDH, RPLP0, EIF4EBP1 0.56 4 
ACTB, PUM1, GAPDH, EIF4EBP1 0.68 4 
ACTB, PUM1, RPLP0, EIF4EBP1 0.69 4 
PUM1, GAPDH, EIF4EBP1 0.70 3 
PUM1, RPLP0, EIF4EBP1 0.72 3 
ACTB, PUM1, GAPDH, RPLP0 0.75 4 
ACTB 0.76 1 
PUM1, GAPDH, RPLP0 0.80 3 
ACTB, PUM1, EIF4EBP1 0.89 3 
ACTB, PUM1, GAPDH 0.97 3 
ACTB, PUM1, RPLP0 0.99 3 
PUM1, EIF4EBP1 1.01 2 
PUM1, GAPDH 1.13 2 
PUM1, RPLP0 1.18 2 
ACTB, PUM1 1.45 2 
PUM1 2.24 1 
 






Figure 20. Gene Expression Pharmacology Inhibitors, RT-qPCR Results 





Figure 18. Continued 





The benefit of physical activity to breast cancer patients is well documented [8, 9, 128-
133], leading to an evolved appreciation for exercise-combined therapies advocated by clinicians 
[93-96]. Despite early animal work which demonstrated increased rates of apoptosis in epithelial 
breast cancer cells exposed to exercise, comparatively little is known regarding the impact of 
exercise on the anabolic activity of breast cancer and whether specific proliferative pathways are 
altered leading to suppressed cell growth and/or induction of apoptosis.  In this study we aimed 
to determine how a breast cancer cell’s anabolic profile is affected by exercise and to identify a 
mechanistic basis of exercise facilitated muscle-cancer crosstalk. Understanding and identifying 
the mechanistic impact of exercise on cellular anabolism, a critical component of tumor growth, 
will facilitate targeted pharma-, chemo- and exercise-combined therapeutic strategies that may be 
used to protect at-risk populations. The data presented here provide a molecular basis for how 
exercise affects the growth and proliferation of breast cancer via the suppression of cellular 
anabolism.  
Several points of evidence support the aforementioned findings. First, exposure of 
epithelial breast cancer cells to medium collected from contracting skeletal muscles resulted in 
suppressed cellular protein synthesis, concomitant with diminished mTOR activity and elevated 
DEPTOR expression. Second, inhibition of mTOR via pharmacology suppresses protein 
synthesis and consequent anabolic signaling in breast cancer cells, with a rescue of DEPTOR 
protein. Previous studies have demonstrated that exercise can alter rates of apoptosis, the flip 
side to mTOR’s regulation of anabolism. Using the same surgical preparation, Westerlind et al. 
demonstrated not only increased apoptosis in cells treated in vitro with perfusate of stimulated 
muscles [25], but increased tumor time to latency and tumor growth retardation with moderate 
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exercise training in vivo [23]. Our data suggests that, the benefit of exercise on breast cancer 
appears to be directed toward the suppression of mTOR activation by facilitating an acute 
overexpression of a potent and specific kinase binding protein called DEPTOR, resulting in 
reduced anabolic responses and increased apoptosis [25]. DEPTOR is an mTOR binding protein 
which inhibits the mTOR activity, and whose expression is low in most cancers [37, 40, 43, 58, 
59] and a characteristic of invasive breast cancer [70]. Our findings are consistent with other 
studies that indicate the control of mTOR activation, and ultimately cancer proliferation, can be 
achieved by indirectly restoring DEPTOR protein through direct interference of its degradative 
pathway [37, 134, 135]. Although future studies need to determine the extent to which DEPTOR 
expression is altered in our model, either through de novo protein synthesis or the rescue from 
degradation, we nevertheless established diminished DEPTOR protein content and concomitant 
mTOR hyperactivity are important contributors to MCF7 cellular proliferation, in vitro. 
Interestingly, the increased expression of DEPTOR was not only concomitant with decreased 
mTORC1 activity as indicated by downstream effectors S6K and 4EBP1, but also a dramatic 
decrease in global protein synthesis with treatment. Thus, in MCF7 cancer cells, diminished 
DEPTOR protein content and concomitant mTOR hyperactivity are important contributors to 
MCF7 cellular proliferation, in vitro. 
With respect to pharmacological regulation of mTOR activity, in vitro treatment of either 
rapamycin, Torin1 or combined suppressed anabolic signaling and consequent cellular protein 
synthesis, with a rescue of DEPTOR protein content, although not as robustly as muscle-
perfusate treatment.  Our results are consistent with previous findings whereby inhibition of the 
mTOR signaling pathway blocks the destruction of DEPTOR [40, 103]. Additionally, inhibition 
of mTOR using Torin1 resulted in an increase in DEPTOR expression, findings consistent with 
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Gao et al [103] who also found blocked DEPTOR destruction with both mTORC1 and mTORC2 
suppression via pharmacology. Inhibition of both mTOR complexes is significant in the context 
of cancer, for without suppression of mTORC2 activity, the complex’s “pro survival function” 
via feedback signaling is maintained, and mTORC1 can remain transiently active, leading to 
continued proliferation [57, 83]. Additionally, we found higher phosphorylation of AKTSer473 in 
TOR1 vs RAP treated cell, concomitant with previously mentioned p70 data, support the 
association between phosphorylated p70Th389 mediated inhibition of the Rictor protein within the 
mTORC2 complex [53, 54, 136] and that signal crosstalk, between the complexes, increased the 
complexity of understanding mTOR regulation [100, 107, 137]. The mTOR kinase is a key 
molecule whose altered activity by exercise can be modeled using pharmacology in culture. 
However, mTOR suppression, per se, cannot solely account for DEPTOR’s acute overexpression 
exercise, as total DEPTOR accumulation by silencing upstream activation of mTOR was less 
than half of what is observed with muscle contractions.  
With the knowledge that DEPTOR is an unstable protein which rapidly degrades upon 
mTOR stimulation [40], we favor the concept that its expression is influenced by the activity of 
its dichotomous interacting partner, mTOR. Moreover, the mTOR signaling network has known 
transduction intermediate proteins that act both upstream and downstream to influence cellular 
anabolic activity, thusly inducing proliferative or apoptotic states [45, 48, 53, 103-110]. Our 
investigations into the expression of these intermediate proteins suggest their dependency on 
mTOR’s activity for their translation. Our data propose that mTOR activity influences the 
availability of a transcript for translation potential via the transcripts association with 
translational machinery. It has been shown that peptide-chain initiation involves specific factors, 
namely eIF4E or eIF3d, that preferentially select transcripts for the translational apparatus, 
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depending on the nature of its 5’UTR [138].  While the newly characterized eIF3d mechanism is 
lesser understood [139],  it is well known that the eIF4E complex can only participate in this 
selective translational process only when mTORC1 is active [140-142]. Therefore, when a 
transcript is cap-dependent, its translation is mTOR-dependent, meaning that it requires 
mTORC1 activity to allow for eIF4E direction of the transcript to the ribosome. If translation of 
the transcript arises when mTOR activity is suppressed, the transcript is thought to be cap-
independent. Our data demonstrate that an increase in DEPTOR mRNA is concomitant with 
decreased mTOR activity, suggesting that its translation is cap-independent 
Unlike cap-dependent transcripts, there are an abundance of transcripts that have internal 
ribosome entry sites (IRES), which allow these transcripts to find the translational apparatus 
independent of eIF4E, and therefore, independent of mTORC1.  It has been speculated that the 
activation of mTORC1 not only selectively directs cap-dependent transcripts to the translational 
apparatus, but also that cap-dependent translation occurs preferentially at the expense of cap-
independent translation.  Cap-independent transcripts are thought to include proteins that respond 
to specific stressors in the cell, impact cell survival, and/or are involved with directing the cell 
into specific phases of the cell cycle [138]. Our pharmacology and exercise model data show 
increased DEPTOR protein coincides with changes in the anabolic state of the breast cancer cell.  
The increased DEPTOR protein content is adjuvant to a suppression of mTOR activity, a 
markedly decreased anabolic rate, and an elevation of apoptosis. We propose that this 
translational dependency of DEPTOR on mTOR’s suppression, which is strongly suggestive of 
cap-independent behavior, is key to its characteristically low expression in invasive breast 
cancers. Furthermore, not only do we demonstrate that hyperactivity of mTORC1 may eliminate 
the possibility of DEPTOR being translated, but also that mTORC1 may also prevent the 
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transcription of the DEPTOR gene. The use of ActinomycinD and Cycloheximide in tandem in 
the present investigation provides a baseline of transcript levels in the cell. As such, at 18h, the 
increase in DEPTOR transcript with rapamycin and Torin1 treatment is not due to the 
preservation of a pre-existing transcript, but the increase mRNA transcription, suggesting that 
mTORC1 suppresses DEPTOR gene transcription, albeit by mechanisms unknown to us at this 
time. Only when we silence mTORC1 do we see a rescue on the protein and transcript of this 
important mTOR binding partner.  Due to mTOR’s hyperactivity in breast cancer, the DEPTOR 
transcript is reduced, and what is bioavailable is not available for translation in the cap-
dependent preferred environment, and thus DEPTOR’s endogenous inhibitory role on mTOR 
eludes the cell.  
We should note that there have been numerous attempts to use pharmacology to silence 
mTOR in an effort to manage cancer proliferation, with limited to marginal success.  While we 
acknowledge that others have demonstrated that the phosphorylation of many mTORC1 
substrates are resistant to rapamycin treatment, including translational regulators [111, 115, 143, 
144] the combination of Rapamycin and Torin1 in our hands did not elicit any significant 
difference in the translation of the DEPTOR protein compared to Torin1 treatment alone. 
Furthermore, with the recognition that pharmacological disruption of the proteolytic mechanism 
responsible to degrade DEPTOR has resulted in limited successful control of mTOR activation 
[37, 134, 135], our findings suggest that the impact of exercise on breast cancer is by directly 
influencing the synthesis of new DEPTOR molecules in a capacity that is far more robust than 
current pharmacological outcomes (Figure 21), and likely not due to a physiological alteration of 




3. STUDY INTERLUDE  
Although the reasons underlying differences in protein expression between exercise and 
pharmacology remain to be fully elucidated, it is enticing to speculate about the mechanistic 






Figure 21. Protein Expression Differences 
CC= Cell Control, Non-Stim= without contraction, E-Stim= with 





The synthesis of specific proteins is dependent upon tight control over translation of their 
mRNA [145]. mTORC1 is tightly linked to several steps of protein synthesis including ribosome 
biogenesis, translation initiation and elongation [100]. Specific mTORC1 active-site inhibitors 
have been shown to significantly reduce overall rates of protein synthesis in proliferating cells 
[56, 107, 112]. Furthermore, the regulation of gene expression for both cellular anabolism and 
apoptosis are sensitive to environmental stimuli resulting in functional aberration of cellular 
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muscle that impact other cells or cell types in organism, are one such example of how the 
investigation into the anabolic transcript may elucidate exercise’s biological regulation on 
cancer. MicroRNAs (miRNA) are small non-coding RNAs found in abundance in skeletal 
muscle that have been proposed as possible myokines. The miRNA have the capacity of 
regulating gene expression post-transcriptionally by masking either the cap-dependent 5’ or 
IRES start codons and preventing the transcript from entering the translational apparatus.  Thus, 
these miRNAs have the capacity to act as negative gene regulators of gene expression on a 
variety of proteins, including those involved with the mammalian target of rapamycin (mTOR) 
pathway. In fact, studies have shown that up to 30% of overall gene expression is affected by the 
presence of miRNA [27], and this regulation has been implicated in the pathophysiology of 
muscle growth, atrophy, metabolism and insulin resistance [57, 148-151]. Overall, discrepancies 
in the translational regulation of altered proliferative factors within the mTOR cascade (Figure 
21) highlight the potential for exogenous sources (i.e., not produced in the cancer cell) of 
anabolic regulation in breast cancer cells, such as microRNA arising from another cell/tissue 
type.  Therefore, a first step in understanding whether microRNA could be a possible regulator in 
the aforementioned altered anabolic capacity of breast cancer will be to profile the appearance of 
microRNA from skeletal muscle, termed myomiRs, with and without exercise.  The hind limb 
perfusion preparation studies in the current study provide an excellent experimental paradigm to 
monitor the appearance of miRNA arising from skeletal muscle and if that appearance is altered 








Underappreciated is skeletal muscle’s ability to release molecules into circulation 
facilitated by muscular contraction. Termed myokines, these molecules have the ability to 
influence many disease states, including breast cancer.  MicroRNAs (miRNA) are small non-
coding RNAs found in abundance in skeletal muscle that impact cellular function by altering the 
availability of mRNA for translation. Mechanistically, this translational alteration is 
accomplished by masking start codons, which prevent the transcript from entering the ribosome, 
and represents a way that cells can modify gene expression post-transcriptionally.  Recent 
interest in miRNA has been focused on findings demonstrating that these post-transcriptional 
modifiers can be released from skeletal muscle and delivered to other cell types in the organism, 
and thus, may be an example of a myokine arising from skeletal muscle and capable of exerting a 
biological action in another cell of the body. We have unique preliminary findings that myokines 
released during electrically-stimulated muscle contraction of hemicorpus-prepared rats affects 
the anabolic activity and capacity of breast cancer cells. When MCF-7 cancer cells were treated 
with perfusate collected during muscle contraction, a significant inhibition of proliferation was 
noted alongside diminished mTOR activity and global rates of protein synthesis. Purpose: The 
purpose of this study was to identify microRNA released into circulation during a controlled hind 
limb perfusion preparation, and how that profile was affected by muscle contractions.  Methods:  
Female Wistar rats underwent a hemicorpus hindlimb perfusion preparation with and without 
electrically-stimulated muscular contractions. RT-PCR analysis of select microRNAs, known to 
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impact cellular anabolism, was performed on both muscle and perfusate samples collected pre- 
and post-contraction (Non-Stim=4. E-Stim=4, respectively). RESULTS: MicroArray analysis 
identified 52 microRNA across all samples, with an average of 65 microRNAs detected per 
sample. Significant differential expression of 8 microRNA E-Stim and Non-Stim samples within 
an animal (p<0.05), and 15 microRNAs between E-Stim and Non-Stim groups (p<0.05) were 
determined. Expression of mir16-5p was 4% higher in hindlimb muscle exposed to E-Stim 
compared to Non-Stim (p>0.05), and was 147% higher in E-Stim perfusate samples compared to 
Non-Stim (p<0.05). CONCLUSION: Results suggest that skeletal muscle is a rich endogenous 
source of cancer microRNA that are released into the circulation, and muscle contraction results 
in the release of specific miRNAs that are associated with altered mTOR signaling. The 
observation that muscular contraction comparable to resistance exercise facilitates the release of 
microRNA into systemic circulation  supports the concept that there is an exercise-facilitated 
crosstalk between muscle and cancer. 
 
 Introduction 4.2.
The burden of breast cancer affects over 2.8 million women in the United States, with 
238,130 new cases in the year 2015 alone [99]; however, this burden can be reduced with 
exercise. Currently there is an evolving appreciation for exercise-combined therapies advocated 
by clinicians [93-96]. Given breast cancer’s prevalence in the United States, and the recognized 
benefit of exercise in breast cancer patients [93-96], identifying and understanding the 
mechanistic impact of exercise on cancer will advance research and may lead to new treatments. 
Our initial experiments have identified a causal role for exercise in cancer 
management/prevention through an, as yet, unidentified release of (a) myokine(s).  A 
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mechanistic understanding of this causal role would have major translational impact in cancer 
prevention and patient survivorship, as even a small 1% reduction in incidence of cancer would 
result in $500 billion in health care savings. Unfortunately, the exercise mechanisms associated 
with a 20-40%% reduction in breast cancer risk are not well understood [2, 8, 9] 
 
Skeletal Muscle as an Endocrine Organ 
Skeletal muscle, the mechanistic machinery of exercise, has established a positive 
association with regard to enhanced activities of daily living and improved quality of life, and its 
protective effect on multiple metabolic disease states [37, 57, 87]. Underappreciated however, is 
that skeletal muscle exhibits an endocrine-like behavior during exercise where exercise-induced 
‘hormones’ are released into circulation in both rodents and humans post muscular contraction 
[19, 20, 35, 88]. Specifically, contracting muscle releases “myokines” (factors), which are 
molecules that effect signaling pathways involved with muscle homeostasis, inflammation, and 
colon cancer, amongst others [19, 22, 89, 90].  
The earliest established connection between myokines and cancer, previously termed 
“fatigue substance”, leading to an inhibited tumor progression dates back to the early 1960s. It 
was found that extract released from rat muscle during passive electrically-stimulated contraction 
resulted in significant tumor growth inhibition when administered via subcutaneous injections 
into tumor-bearing rodents [4, 21, 24]. Most recently, our lab has contributed to the field’s 
current findings that in situ produced muscle-contraction medium significantly inhibits cancer 
cell growth, proliferation in vitro [22, 26, 91, 92] potentially through the altered cellular 
anabolism. Furthermore, expression differences of key anabolic proteins between muscle-
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perfusate and pharmacology data (see above) lead to enticing speculation about the mechanistic 
contribution of contracting skeletal muscle on gene expression. 
 
MicroRNA 
MicroRNA are endogenous, small, but mature, single stranded RNAs with gene silencing 
capabilities. These small, non-coding ~22 nucleotide sequence long molecules are believed to 
control 30% of overall gene expression [27]; thus they are implicated in the pathophysiology of 
muscle growth, atrophy, metabolism and insulin resistance [57, 148-151]. These miRNA have 
post-transcriptional abilities allowing them to act as negative gene regulators of gene expression. 
This is accomplished through association with the RNA Induced Silencing Complex (RISC), 
which exposes an unpaired strand of the miRNA, directing it to bind to messenger RNAs 
(mRNAs) with a partially complementary sequence [152]. Of particular interest to us, are the 
recent investigations that miRNA can be manufactured in one cell, packaged in exosomes or 
protein carriers, and released into circulation where they can be taken up by other cells or even 
cell-types [153]. Upon an miRNAs uptake by a receiving cell, resultant translation repression or 
mRNA degradation can occur, subsequently modulating protein expression post-transcriptionally 
[145].  
A relevant and key feature of miRNAs is their remarkable stability; they are well 
preserved both in their tissue of origin as well as in circulation, as they are often packaged in 
vesicles or on carrier proteins to protect them from RNAse activity in the blood.. In circulation, 
these non-coding nucleotide sequences may be delivered to a recipient cell to regulate 
translational activity of targeted genes. In breast cancer research, circulating microRNA, 
collected in biological fluids, act as minimally invasive biomarkers for disease progression and 
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risk factors. Recently, Heneghan et al. showed that circulating tumor-associated microRNAs 
have the potential to serve as a marker of breast cancer in its earliest stages, providing 
information regarding histologic features, hormone receptor and lymph node status [154]. Basic 
experiments of breast cancer and miRNA have evaluated microRNA’s role in cell growth and 
proliferation in vitro, directed primarily to apoptotic and autophagy pathways [29, 60-69]. 
Moreover, miRNA expression is observed to be altered in physiological states, such as 
exercise. Additionally, miRNA have previously been found in abundance in skeletal muscle, 
thusly making them attractive candidates for membership under the myokine umbrella. 
MyomiRs, microRNA released by skeletal muscle, have been found to regulate multiple facets of 
muscle development [149, 155] and myogenesis [156-158]. A myomiR of interest due to it 
absence or downregulateion in many types of cancers is miR16-5p-1 [159-162]. In breast cancer, 
which has low basal expression of miR-16-5p-1, the overexpression of this microRNA attenuates 
cellular growth and proliferation, and promotes apoptosis [159, 163].  Interestingly, it has also 
been implicated in regulating protein synthesis through the mTOR network [151, 164, 165].  
Ramaiah et al [165] demonstrated that overexpression of exogenous sourced miR-15/16 led to 
inhibition of cell proliferation, with demonstrated direct binding of miR-16 to a subunit of 
mTORC1’s downstream effector p70S6K1. These findings encourage the evaluation of miR-16-
5p-1 as a myomiR release during contraction to potentially facilitate altered mTOR-mediated 
anabolism with muscle-breast cancer crosstalk. 
In context of cellular anabolism, changes in mitotic capacity and proliferation can both be 
attributed to changes in gene expression at the translational level. Thus, many pathways have 
been implicated in the development and progression of breast cancer. Among them, the mTORC 
signaling network has garnered much acclaim due to its superlative role as regulator of 
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coordinated cell growth, proliferation and survival. With the knowledge that mTORC1 is tightly 
linked to several steps of protein synthesis including ribosome biogenesis, translation initiation 
and elongation [100], the investigation into differences in anabolic transcript of a cancer cell 
with muscle-contraction exposure may elucidate exercise’s biological regulation on tumor- and 
carcinogenesis [101, 102]  Furthermore, the mTOR kinase’s sensitivity to environmental stimuli 
and cellular metabolic environment further encourage investigation into its response to exercise 
exposure beyond metabolic substrate and oxygen availability. However, it remains unclear as to 
whether anabolic repressor microRNA are found in circulation following muscle contraction, and 
whether they have the ability influence the bioavailability of mTOR proliferative factors. 
 
As such, the purpose of this study was to profile microRNA released from skeletal 
muscle into circulation, with and without lower limb muscular contractions to determine if the 
myomiR profile is altered by exercise.  Results herein illustrate the secretome profile of both 
quiescent and maximally contracting skeletal muscle, and we offer speculation on how the 
contracting profile may affect breast cancer cells. 
 
 Methods 4.3.
Muscle Perfusate and Skeletal Muscle Collection 
Female Wistar rats (N=10) 8-12 weeks of age were purchased from Charles River 
Laboratories (Wilmington, MA). All procedures were approved by the Institutional Animal Care 
and Use Committee at Texas A&M University. Animals were house two-rats per cage under 
standard 12h photoperiod, provided with normal Rat Chow with water ad libitum. Following a 2 
day acclimation period after arrival, animals underwent a non-survival hemicorpus hind limb 
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perfusion preparation (HHLP) (Figure 7) as described previously [91, 92, 122-125]. Briefly, 
midline to caudal end of the animal was surgically prepared so both hind limb limbs could be 
perfused with an oxygenated Krebs-Heinseliet Buffer during electrically stimulated muscle 
contraction. Electrical stimulation was administered using a stimulator (Model #) (Grass 
Instruments, West Warwick, RI), a force transducer (Warner Instruments, Harvard Bioscience 
Inc., Holliston, MA) at a surgically exposed sciatic nerve on a single hind limb of the animal. 
Perfusate medium was maintained at 31.7°C using a bipolar temperature controller (Model # CL-
100, Warner Instruments, Harvard Bioscience Inc., Holliston, MA) and administered at a flow 
rate of 12ml/min, by peristaltic pump (MPL 8-Channel) (Watson Marlow, Marlo, United 
Kingdom).  
Perfusion sample collection is depicted previously in Figure 8. During perfusion, medium 
was collected on ice in 50ml sterile conical tubes (Corning Inc., Corning, NY) before electrical 
stimulation (Non-Stim, NS), during electrical stimulation (E-Stim, ES), and following electrical 
stimulation (Post-Stim, PS). Following collection, samples was centrifuged at 2500 rpm at 4°C 
to remove red blood cells and the supernate was then stored at -80°C until analysis. Skeletal 
muscles of both hind limbs were anatomically separated into soleus, plantaris, gastrocnemius and 
snap frozen in liquid nitrogen, and stored at -80°C until analysis. 
 
miRNome Profiling of Muscle Perfusate 
Sample Preparation. A total of 8 samples (NS=4, ES=4) were profiled for microRNA 
Total RNA was extracted by using the miRCURY exosome RNA isolation kit #300102 (Exiqon, 
South Korea), and then followed by miRNeasy Micro Kit #217084 (Exiqon, South Korea). Three 
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RNA spike-ins (UniSp2, UniSp4 and UniSp5) were pre-mixed, each at different concentration in 
100 fold increments, added to samples, and used as an RNA isolation control. 
RT-qPCR.  All microRNAs were polyadenalyted and reverse transcribed into cDNA in a 
single reaction step. A total of 4 µl of RNA was reverse transcribed in 20 µl reactions using the 
miRCURY LNA Universal RT microRNA PCR, Polyadenylation and cDNA synthesis kit 
(Exiqon, South Korea). To confirm reverse transcription and amplification efficiency in all 
samples, UniSp2 was used as a spike in (RNA Spike-In Kit, ID#339390, Exqion). cDNA was 
diluted 50 x and assayed in 10 ul PCR reactions using a pipetting robot; each microRNA was 
assayed once by qPCR on the miRCURY LNA miRNA Human Cancer Focus PCR Panel CAT# 
YAHS-102Y(  EXIQON, South Korea), using ExiLENT SYBR® Green master mix. A total of 
88 primers were assayed. Negative template controls (NTC) were profiled similar to the samples. 
The amplification was performed in a LightCycler 480 Real-Time PCR System (Roche) in 384-
well plates. The amplification curves were analyzed using the Roche LC software, both for 
determination of Cq (by the 2nd derivative method) and for melting curve analysis.  
Data Analysis. The amplification efficiency was calculated using algorithms similar to 
the LinReg software. All assays were inspected for distinct melting curves and the Tm was 
checked to be within known specifications for the assay. Assays with several melting points, or 
with melting points deviating from assay specifications were flagged and removed from the data 
set. Reaction amplification efficiency was set at 1.6 or above. Additionally, assays must be 
detected with 5 Cqs less than the negative control, and with Cq<37 to be included in the data 
analysis. Data that did not pass these criteria were omitted from any further analysis. Cq was 
calculated as the 2nd derivative.  
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Normalization. Data were normalized to correct for potential overall differences between 
samples using as identified best by NormFinder software (Anderson, C. et al). The formula used 
to calculate normalized Cq values was as follows: 
Normalized Cq = average Cq – assay Cq (sample) 
 
RT-qPCR Validation in Muscle Perfusate and Muscle Tissue 
Sample Preparation. Enriched and Isolated microRNA samples from miRNome profiling 
were utilized. Total RNA from pooled soleus and gastrocnemius muscle tissue samples were 
manually extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA) and 1-Bromo-3-
chloropropane (Biomedical Research Centre) protocol, and precipitated in isopropanol. 
Following precipitation, RNA was treated with a series of ethanol washes to prevent downstream 
salt inhibition, and then re-suspended in 50ul of nuclease free water. RNA concentration was 
then quantified by a Nanodrop using a NanoDrop 1000 spectrophotometer (Thermo Scientific, 
Waltham, MA) according to manufacturer’s specifications. RNA integrity (RIN) was assessed on 
a 4200 TapeStation System (Agilent Technologies, Santa Clara, CA), which assigned a RINe 
value on a scale of 1 to 10. RNA samples with RINe quality values >7.5 were included in RT-
qPCR assays. 
RT-qPCR. Reverse transcription for cDNA synthesis was performed using TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) with 40ng and 
200mg of total RNA (perfusate vs muscle samples, respectively) in reactions of 15ul according 
to manufacturers instructions. Corresponding negative reverse transcriptase reactions (NRT) 
were also prepared for each sample. miRNA expression of target miRNA was quantified with 
real time PCR using Applied Biosystems 7900HT Fast Real-Time PCR System (Carlsbad, CA). 
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TaqMan MicroRNA Assay has-miR-16-5p (ID# 000391) and US snRNA (ID 1973) were 
handled according to the manufacturer’s instructions. Quantitative PCR was performed in 
triplicates of 20ul reactions using 1X TaqMan Universal Master Mix II, no UNG (Applied 
Biosystems, Carlsbad, CA) with corresponding NRT and no template controls (NTC). Thermal 
conditions were as follows: 10min at 95°C, and 15s at 95°C with 1min at 60°C for 40 cycles. 
Expression of target gene was normalized to US snRNA. All data analysis was conducted with 
Sequence Detection Software v 2.2.2 (Applied Biosystems, Carlsbad, CA). 
 
Statistical Analyses 
MirNome Profiling of Muscle Perfusate. The normal distribution of the data was assessed 
by a Shapiro-Wilks normality test. If the data were normal, a t-test was performed for 
microRNAs detected in at least three samples per group to assess differential expression between 
Non-Stim and E-Stim groups.  If the data were not normal (p>0.05), a Wilcoxon test was 
performed on all assays detected in at least three samples per group. A chi-square test was 
performed on all assays to detect if any assay was under represented in one of the two groups. A 
low p-value from chi-square test indicated that the presence of the miRNA was different between 
the E-Stim and Non-Stim groups.  
RT-qPCR Validation in Muscle Perfusate and Muscle Tissue. A t-test was performed to 
assess differential expression of miR16-5p-1 between Non-Stim and E-Stim samples of exercise 
perfusate and muscle, followed by Fisher LSD post hoc test (SigmaStat 3.5; Systat Software Inc., 






miRNome Profiling of Muscle Perfusate 
Profiling of perfusate samples was successfully completed for all samples (n=8). Controls 
(NTC and RNA spike-in) indicated good technical performance of the profiling experiment. No 
inhibition during qPCR was detected. Unsupervised analysis demonstrated that samples from the 
E-Stim group are grouped together and samples from the Non-Stim group are grouped together. 
52 microRNA were identified across all samples, with an average of 65 microRNAs detected per 





Figure 22. Graphical Illustration of MicroRNA Content.  
The bars represent the number of microRNAs detected and the line shows the average 
Cq value for the commonly expressed microRNAs. On average, 65 microRNA were 




Using NormFinder the best normalizer was found to be the average of assays detected in 
all samples. All data were normalized to the average of assays detected in all samples (average – 
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level of 0.05 (Figure 23). When comparing grouped E-Stim to Non-Stim samples, 8 microRNAs 
were found to be differentially expressed between E-Stim and Non-Stim samples (p<0.05) 
(Table 2). When comparing paired E-Stim vs Non-Stim samples, 15 microRNAs were found to 
be differentially expressed (p<0.05), with one passing a Benjamin-Hochberg correction (p<0.05) 




MirName Fold Δ (+S) p-value 
hsa-miR-143-3p  -2.4+0.15 0.00043 
hsa-miR-7-5p  -1.3+0.06 0.0067 
hsa-miR-24-3p  -1.2+0.09 0.0074 
hsa-miR-145-5p  -3.2+0.53 0.0082 
hsa-miR-196a-5p  1.8+0.19 0.015 
hsa-miR-125b-5p  -2+0.4 0.017 
hsa-let-7d-5p  -1.3+0.16 0.018 
hsa-miR-130a-3p  -1.9+0.4 0.019 
hsa-miR-99a-5p  -2+0.45 0.023 
hsa-miR-15a-5p  -1.8+0.41 0.026 
hsa-miR-93-5p  2+0.49 0.029 
hsa-miR-10b-5p  -1.9+0.5 0.032 
hsa-miR-16-5p  1.4+0.24 0.033 
hsa-miR-195-5p  -1.5+0.3 0.034 
hsa-miR-126-3p  -1.5+0.34 0.038 
 
Table 2. MicroRNA Profiling, Paired t-Test Results 
This table shows the standard deviation (SD) across groups, followed by the average normalized Cq 
values for each group, and fold change between the two groups. The last column shows the p-value 







MirName Avg ∆Cq  (+ SD) Fold Δ p-Value 
Non-Stim E-Stim 
hsa-let-7d-5p  -0.77+ 0.13  -0.4+0.14 -1.3 0.008 
hsa-miR-181b-5p  -2.4+0.29  -3.2+0.38 1.7 0.02 
hsa-miR-101-3p 0.82+0.24  -1.7+0.46 1.8 0.027 
hsa-miR-99a-5p  -2.2+0.5  -1.2+0.51 -2 0.035 
hsa-miR-143-3p  -2.3+0.67  -1+0.65 -2.4 0.036 
hsa-miR-145-5p  -0.28+1 1.40+0.62 -3.2 0.036 
hsa-miR-186-5p  -4.3+0.33  -5.1+0.37 1.8 0.037 
hsa-miR-181a-5p  -1.1+0.25  -1.7+0.38 1.5 0.047 
 
Table 3. MicroRNA Profiling, t-Test Results 
This table shows the standard deviation (SD) across groups, followed by the average normalized Cq 
values for each group, and fold change between the two groups. The last column shows the p-value 







Figure 23. Volcano Plot of Differential MicroRNA Expression 
The volcano plots shows the relation between the p-vales and the ∆∆Cq. Highlighted are microRNAs with p-values 




RT-qPCR Validation in Muscle Perfusate and Muscle Tissue 
Expression of mir16-5p-1 was 4% higher in hind limb muscle exposed to E-Stim 
compared to Non-Stim (p>0.05), and was significantly 147% higher in E-Stim perfusate samples 





Figure 24. miR16-5p-1 RT-qPCR Results 
Data are expressed at relative expression (RQ=2-∆∆Ct). Statistical significance: a= 

















































Figure 25. Heat Map and Unsupervised Hierarchical Clustering of top 50 microRNA. 
Results of the two-way hierarchical clustering of top 50 microRNAs and samples. Each row represents one microRNA, and each column represents one sample. The microRNA-clustering tree is shown on the left. Relative 




In the United States, breast cancer accounts for 30 % of all new cancer diagnoses in 
women alone [1]. The benefit of physical activity to breast cancer patients is well documented 
[8, 9, 128-133], leading to an evolved appreciation for exercise-combined therapies advocated by 
clinicians [93-96]. Skeletal muscle, the mechanistic machinery of exercise, has a unique ability 
to release molecules into systemic circulation, which have auto- and paracrine capabilities [8, 19-
22]. Despite the knowledge that anabolic protein expression dictates function, and that skeletal 
muscle is a potent reservoir of endogenous gene repressors, microRNA (myomiRs), little is 
known regarding circulating myomiRs as potential sources of cancer anabolic gene repressors. In 
this study we aimed to evaluate the effect of contraction on the microRNA ‘secretome’ of 
skeletal muscle, and to profile expression of circulating myomiRs that may impact the growth 
and proliferation of cancer. As such, the present study is an “intermediate” investigation of 
mTOR gene expression regulation, evaluating the role of exercise as facilitator of muscle and 
breast cancer crosstalk observed in dissertation work discussed above (study 1 and 2), in addition 
to previously published work [25, 91].  
 Several points of evidence support this notion. First, muscular contraction 
comparable to resistance exercise facilitates the release of microRNA into systemic circulation. 
The physiological relevance of systemic miRNA is dependent upon a mature miRNA’s stability 
and concentration in biofluids to maintain functional integrity to carry-out post-translational 
modifications of target genes on recipient cells [28, 166, 167]. Aligning with our results, other 
studies have shown detectability of circulating microRNA after incubation at room temperature 
[154, 168] and after multiple freeze-thaw cycles [166, 169]. Differences in mTOR network gene 
expression between muscle perfusate (study 1) and pharmacology (study2) reported above 
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suggest that an endogenous molecule arising from skeletal muscle, such as a myomiR, acts a key 
physiological mechanism contributing to the benefit of exercise above pharmacology alone.  
Second, the secretome of skeletal muscle differs at rest and during electrically-simulated 
contraction via the nerve. Previous studies have demonstrated that miRNA can be released both 
actively and passively into systemic circulation [170-175]. Our data show expression differences 
in Non-Stim (quiescent) and E-Stim (contracting) medium collected in real-time from the hind 
limbs of female rats. This collection technique, which eliminates the candidacy of other tissue 
and organs as sources of microRNA, highlights a direct connection between skeletal muscle 
contraction and altered cancer anabolism observed in dissertation work discussed above (study 1 
and 2), in addition to previously published work [25, 91]. The earliest investigation that 
demonstrated neoplasia inhibition with exercise in a rodent model was by Rusch and Kline in 
1944, utilizing a rotating drum as the exercise mode [176]. The vast majority of exercise and 
cancer prognoses in both rodent and human models have utilized acute e-stim or aerobic exercise 
training. Even though the use of treadmill and wheel running is accepted as a surrogate model for 
physical activity and training effects in humans, isolated muscle contraction and resistance 
exercise are associated with greater muscle recruitment and systemic myokine secretion [19, 
177-179]. As such, the hemi-corpus hind-limb perfusion preparation with an electrically-
stimulated for muscle contraction via the sciatic nerve methodology utilized here provided a 
controlled and directive approach to evaluate muscle involvement of exercise on cancer, 
eliminating confounding variables such as the voluntary exercise response variability, hormonal 




 With respect to the chemotherapeutic impact of muscle contraction on breast 
cancer, our data indicate that ‘exercise’ has the potential to facilitate crosstalk between muscle 
and breast cancer, and this impact directly affects anabolic gene expression leading to disrupted 
or attenuated growth. Previously, collaborative research has shown miR16-5p-1 expression is 
significantly elevated in quiescent skeletal muscle in conjunction with normal anabolic function 
and elevated expression of the mTOR inhibitory protein, DEPTOR [151].  Interestingly, after 
anabolic-promoting exercises in skeletal muscle, there is a significant reduction of miR16-5p-1, 
leading to a loss of DEPTOR and heightened anabolic function.  Based on the current studies, we 
now know that the loss of miR16-5p-1 after exercise may be due to the release of that molecule 
into the circulation.  The expression of miR16-5p-1 is noted to be absent or downregulated in 
many types of cancer [159-162], and with the dysregulated anabolism in some muscle diseases 
[151].  In circulation, miR-16-5p-1 is encapsulated in microvessicles, protecting it from high 
RNAse activity of blood serum and plasma [183]. As such, miR-16 is generally thought to be a 
key tumor-suppressive miRNA and a likely candidate for myokine designation. In breast cancer, 
which has low basal expression of miR-16-5p-1, the overexpression of this microRNA attenuates 
cellular growth and proliferation, and promotes apoptosis [159, 163]. Our investigation showed 
significant increase in circulation of miR-16-5p-1 in muscle perfusate. Results of the targeted 
RT-qPCR validation experiments supported the results of the microarray, demonstrating a 
significant elevation in miR16-5p-1 in the E-Stim muscle perfusate as compared to Non-Stim, 
without a decline of expression in contracting muscle, suggesting that this microRNA was being 
manufactured during contraction for reasons unknown. Results from  study 1 reported above 
showed significant elevation in DEPTOR protein expression in MCF7 cells cultured in the same 
muscle-perfusate used here-in (study 3). Collectively, this suggests that miR-16-5p-1 expression 
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may contribute to altered anabolic capacity of breast cancer cells, potentially through repressed 
anabolic gene expression. Future work from our laboratory will systematically assess the impact 
of miR-16-5p-1 on cancer cells, as well as define the anabolic targets it impacts.  Those studies 
are beyond the scope of the current study. 
Moreover, myomiRs that would target anabolic proteins and serve to repress their 
translation would be likely candidates to be released from skeletal muscle with contraction.  This 
would be a means to protect/elevate the contribution of mTOR anabolic signaling to muscular 
adaptations like hypertrophy. Thus, upon secretion into systemic circulation, whether packaged 
in exosomes or microvessicles, myomiRs could be delivered to recipient surrounding cells, 
including cancer, to impart their post-translational control to suppress growth and cellular 
proliferation capacity of tumors.   
When extrapolating miRNA expression differences found in our study, it is important to 
reiterate that the contraction model used in this study is most comparable to maximal activation 
with resistance exercise that is accompanied by complete motor recruitment of the muscle, albeit 
without any load imposed. Others have not only shown that miRNA expression differs over the 
exercise and recovery duration, but also by mode of exercise performed [155, 175, 184-192], 
which may be due to loads imposed on the muscle or the amount of muscle mass recruited to 
perform the work. Furthermore, fiber type specificity may also play a role, and the participation 
of specific fiber types is often dictated by the forces necessary to overcome loads imposed upon 
them.  As such, lack of distinction in exercise mode and intensity may explain variation in 




In conclusion, this investigation collectively provides a mechanism of exercise-facilitated 
muscle and cancer crosstalk through the secretion of known cancer associated microRNA. 
Understanding myomiR expression levels and their clinical significance as it pertains to tumor 
progression, may provide insight into the pathobiology of breast cancer cell growth and 
proliferation observed with combined exercise-therapeutics. Further elucidation of the transport 
of these molecules in circulation and their affinity for specific gene targets within the anabolic 






Collectively, our results provide insight how exercise may act as a modulator for muscle and 
cancer crosstalk, altering vital anabolic signals within cancer cells through manufacture and 
release of factors into the circulation. Our data strongly suggest that the mTOR-DEPTOR 
interaction is an important participant in cancer proliferation and that the rescue of DEPTOR, 
either through silenced mTORC1/2 signaling or altered protein expression of DEPTOR, may 
serve a critical role in the reduced proliferation/elevated apoptosis in response to the medium 
perfused through contracting skeletal muscle. A critical question for the future is whether 
regulated DEPTOR expression, endogenous or exogenous (i.e., via genetic engineering), can 
contribute to the suppressed anabolism in a cancer cell, long-term. As such, efforts focused on 
the rescue of DEPTOR expression as opposed to altering its degradative-pathways, may be 
therapeutically helpful to counteract the limited success of rapalogs and first generation 
inhibitors in the clinic. Furthermore, the discovery of miRNA differences in skeletal muscle 
during and after contraction support the naming of skeletal muscle as an endocrine organ. These 
data suggest that endogenous muscle miRNA, myomiR, with their potential regulation of 
messenger RNAs that encode proteins, are suitable candidates of myokine influence. The data 
presented in these studies indicate that (a) factor(s) arising from skeletal muscle affects the 
anabolic function and survival of cancer cells, which appears to be directly focused on the key 
anabolic pathway involving mTOR.  Subsequent studies using pharmacology to affect mTOR 
activation were largely successful in reproducing that work, albeit on a smaller scale.  
Collectively, our data indicate that the mechanistic target of muscle and breast cancer crosstalk 
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CC 676.38 600 979 10 
CC + ActD 216.52 203 187 9.9 
CC + ActD +CYX 188.56 175 137 9.5 
CC + CYX 445.69 446 378 9.6 
VC 585.46 570 449 9.7 
VC + ActD 195.57 165 159 9.8 
VC + ActD +CYX 216.48 198 187 9.7 
VC + CYX 359.21 329 238 9.6 
RAP 441.94 405 275 9.8 
RAP + ActD 215.34 197 170 9.7 
RAP + ActD +CYX 131.34 113 97.1 9.8 
RAP + CYX 287.42 277 215 9.7 
RAP+TOR 300.61 269 284 9.4 
RAP+TOR + ActD 145.93 113 92.4 9.6 
RAP+TOR + ActD +CYX 113.93 101 85.3 9.5 
RAP+TOR + CYX 195.88 177 158 9.5 
TOR 366.74 340 195 9.8 
TOR + ActD 134.87 118 97.2 9.8 
TOR + ActD +CYX 116.14 98.6 80.4 9.4 
TOR + CYX 230.09 205 139 9.7 
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Table 5. qPCR Target Gene Assay Details 













(bp) Assay ID 
EIF4EBP1 1978 NM_004095.3 877 2-3 69 Hs00607050_m1 
GAPDH 2597 NM_001289746.1 NM_002046.5 
1407                       
1285 
2 
3 122 Hs_99999905_m1 
RPLP0 6175 NM_001002.3 NM_053275.3 
1105                      
1289 
3 
3 105 Hs_99999902_m1 
ACTB 60 NM_001101.2 1793 1 171 Hs_99999903_m1 
PUM1 9698 NM_001020658.1  NM_014676.2 
5416                     
5410 
20-21                             
20-21 77 Hs00982775_m1 
 
Table 6. qPCR Reference Gene Assay Details 









 Surgical Preparation 8.1.
Equipment Calibration: 
Warner Instrument Box (Perfusate Temperature Regulator) 
1. Attach water hose to tap and use a light flow 
2. Set temperature using the “set temperature” dial 
3. Connect the thermometer to the “monitor temperature” input 
Note: The catheter dissipates heat, so set temperature just above 36.8°C (~37°C) because 
the end temperature of the catheter (essentially the perfusate entering circulation) needs 
to be 36.8°C.  
 
Peristaltic Pump: 
- When not in use, unclamp the tubes on the box 
- When in use, have the clip at the same slot 
- To lock hold “start” and “stop” at the same time 
- Pump rate: 12ml/min 
 
Saline Drip: 
- Invert the saline pump/tube/drip to allow it to fill to protect from bubbles emptying into 
the system (do this before attaching the catheter to the animal) 
- Monitor this level to see if there is a change in the systemic pressure in the animal 
 
Procedure And Equipment Set-Up: 
1. Turn on / hook up O2(g) 
2. Turn on pump pro and set at correlated rpm 
3. Pour perfusate into glass vial 
4. Divert O2 tank to flow into the glass (note: you only want slow low bubbles to oxygenate 
the perfusate) 
5. Turn on glass turner so that the vial of the perfusate is constantly moving 
6. Set-up overflow vial in draw and place surgery overflow tube in there 
7. Turn on water flow, turn on temperature box 
8. Check that electrodes are connected. 
9. Set up 50ml conical collection vial 
 
Surgical Procedure: 
1. Inject 0.75ml of Ketamine into intraperitoneal cavity 
2. Check animal for negative hind limb reflex 
3. 1st Cut: cross abdominal cut with angled proximal ends (blunt dissectors) 
4. 2nd Cut: cut a deep mid sagittal line proximal to sternum-xiphoid process, through the 
abdominal and thoracic musculature. Be careful not to pierce gastrointestinal organs, 
kidneys or lobes of liver. 




6. Use gauze pads to separate gastrointestinal tissue, reproductive tissue from fat and fascia. 
Make sure to push fecal matter away from the pelvic floor to all room for clean ties 
7. 1st Tie: place surgical silk under the long intestine and fallopian tubes, including the 
bladder and below the fallopian bifurcation. Make sure the double tie is as close to the 
pelvic floor before cutting off excess thread. 
8. 2nd Tie: place surgical silk under the proximal intestine up by the liver, under the lobes of 
the liver, make sure not to include the lobes of the kidney. Cut tissue and discard. 
9. Wipe body cavity up to the kidneys, main descending artery and vein. Keep the cavity 
and tissue moist by soaking with saline to prevent tearing vascular tissue. 
10. OPTIONAL: Step 10 is optional. Tie off the kidney bifurcation with two separate ties (left 
tie, right tie). 
11. 3rd and 4th Tie: Find kidney artery bifurcation, lift up with hook forceps, grab with 
forceps, and pull surgical silk through. Make left and right ties.  
12. Re-wipe body cavity and moisten with saline. 
13. 5th & 6th Tie: tie off two other distal bifurcations to eliminate perfusion flow to other 
distal tissue. 
14. Prepare for Cannulation: The artery lays to the left of the large veins. Pull on the side 
tissue to show the interconnecting space between the artery and vein. Use forceps and 
blunt dissectors to tweeze away the tissue to separate the artery and vein. Note: Use the 
nose of the dissectors and/ forceps) to tweeze apart the space. Pinch the forceps closed 
and place on space, then slowly allow the forceps to open to the length of the vein and 
artery in a stroking motion with light downward pressure. 
15.  7th Tie: leave forceps under the separated artery. Feed the tie under the forceps and make 
a loose tie. 
16. 8th Tie: repeat 7th tie but distal to 7th tie , on the artery, above the bifurcation. 
17. 9th & 10th Tie: use forceps to tweeze under the vein and expose on the other side. Be 
careful not to knick the vein. Pull two sutures under the veins and place them parallel to 
ties 7 and 8. Create loose loop ties. 
 
Canulate Artery: 
18. Moisten vascular tissue and body cavity with saline. 
19. Cannulate as proximal as possible to the distal bifurcation, below the 7th tie. 
20. Hold the catheter needle, bevel up. 
21. Hold the catheter with cannulation forceps on outside of the artery tissue, as the needle is 
gently push/inserted into the artery, threading it deep toward the caudal bifurcation, 
through the loose loop tie. 
22. Take the distal 8th tie and tie around the catheter, over the artery tissue. 
23. Tie off 7th tie which is already through the proximal artery tie. Again, ties around the 
cannula and the artery tissue. 
24. Attach the artery perfusion line. Be careful not to over twist as it will twist the cannula 




25. Moisten vascular tissue and body cavity with saline. 
26. Cannulate the vein as proximal as possible to the distal bifurcation, below the 9th tie. 
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27. Hold the catheter needle, bevel up. 
28. Hold the catheter with cannulation forceps on outside of the vein tissue, as the needle is 
gently push/inserted into the vein, threading it deep toward the caudal bifurcation, 
through the loose loop tie. 
29. Take the distal 10th tie and tie around the catheter, over the artery tissue. 
30. Tie off 9th tie which is already through the proximal vein tie. Again, ties around the 
cannula and the vein tissue. 
31. Attach the perfusate collection line. Be careful not to over twist as it will twist the 
cannula and tear the vascular tissue. 
32. Switch on peristaltic pump. Set timer to 0m and begin 8min of flush. 
 
Electrode Placement: 
33. Locate the hip socket. Using sharp dissection scissors, cut away skin at the hip to 
exposure muscle. 
34. Take sharp dissection scissors and create a proximal-distal opening cut on the fascia line. 
35. Using blunt dissection scissors, widen the cut in the muscle with its natural separation 
space. 
36. Push on lower hip to expose a white stipe (sciatic nerve) 
37. Hook both positive and negative electrodes around the sciatic nerve. Moisten with saline 
to ensure the nerve does not dry out. 
 
In-situ Perfusate Collection 
38. Carefully move the animal to the perfusion cage 
39. Cover body cavity with 4x4 gauze pad soaked in saline. Continue to keep the gauze pad 
moist during perfusion. 
40. After 8m flush, reset timer to 0m. Begin electrical stimulation at 20V increments, 
increasing to ensure continuous muscle contraction. 
41. Following e-stim collection, cease electrical stimulation, set time to 0m and begin post-
stim flush.   
 
 
 Krebs-Heinseliet Buffer Recipe 8.2.
The following methods are appropriate perfusion procedures in the hemicorpus hind limb 
perfusion preparation: 
 
Stock Solution Recipe: 
 
1. Measure out the following volumes in a 6L volumetric flask. 
NaCl-692.3g  Q.S. to 4L with di H20 (25x) 
KCL-35.34g  Q.S. to 1L with di H20 (100x) 
CaCl2 . 2H20 -37.35g  Q.S. to 1L with di H20 (100x) 
KH2PO4 – 16.19g  Q.S. to 1L with di H20 (100x) 
MgSO4. 7 –H20 -29.33g Q.S. to 1L with di H20 (100x) 
 




1. Weigh out 2.1g of NaHCO3- per liter (L) of fresh solution, and mix into 500ml of Di H20 
to dissolve. 
2. Take NaHCO3- 500ml solution and gas for 30min with 95% ⁰2; 5% CO2.  
3. Prepare Working Buffer Solution while NaHCO3- solution is being gassed. 
 
Working Buffer Solution: 
 
1. Measure out the following volumes in a 1L volumetric flask. 
118.5 mM  NaCl-40ml 
4.7 mM KCL-10ml 
3.4 mM CaCl2 . 2H20-10ml 
1.2 mM  KH2PO4 – 10 ml 
1.2 mM MgSO4. 7 –H20 – 10 ml 
 
2. Take the mix with NaHCO3 solution and Q.S. to 1 L (using di H20) 
3. Once working solution is completely mixed, add Fraction V Bovine Serum Albumin 
(BSA) to obtain 3.5% solution (3.5g/100ml). BSA should be present both in the 
transport/wash and incubation buffers.   
4. Add dextrose to obtain 90-100 mg% 
5. Leave solution to mix with stir bar until BSA is completely dissolved (~1h). 
6. To store, seal the volumetric flask keep in cold room or fridge at -4C until ready to use  
 
Note: Shelf life of working buffer is2-3 days at -4C. Transport buffer should be cool but 





Figure 27. Hemicorpus   Perfusion Preparation, Surgical Images 
A) Placement of surgical ties, B) Artery and vein cannula placement, 
C) Sciatic nerve exposure and electrode placement, D) Final perfusion 
preparation 
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